Back to top

Call for Public Members, Canadian Expert Drug Advisory Committee (CEDAC) and Compus Expert Review Committee (CERC)

CEDAC is an independent advisory body with expertise in drug therapy
and drug evaluation. As part of the Common Drug Review, CEDAC makes
recommendations to the participating federal, provincial, and
territorial publicly funded drug plans regarding the inclusion of drugs
on their formularies. The committee's approach is evidence-based and
considers the clinical effects and cost effectiveness of drugs compared
with other available therapies.

CERC is an independent advisory body that makes recommendations related
to the identification, evaluation, and promotion of best practices in
drug prescribing and use in Canada. The approach is evidence-based and
the advice reflects current medical and scientific knowledge, as well
as clinical practice in the Canadian health care system.

CEDAC and CERC are appointed by, and report to, the Board of Directors
for the Canadian Agency for Drugs and Technologies in Health (CADTH).
CADTH has recently decided to expand the membership of CEDAC from
eleven to thirteen with the inclusion of two Public Members. The Board
has recently approved the constitution of CERC, in principle, which
will also include two Public Members. Public Members for each committee
will be selected to represent the broad public interest and will have
some experience or demonstrated interest in issues related to health
care, at the community, regional or national level, and will ideally
have some experience working with committees. They will serve in the
capacity as a member of the general public and not as a representative
of any specific interest, group, or organization. Public Members will
be full members of CEDAC or CERC with the same responsibilities and
expectations and subject to the same terms and conditions for all
members of the committee.

Members of CEDAC and CERC must abide by CADTH's Conflict of Interest
Guidelines and Code of Conduct. An honorarium is paid to members for
their preparation and meeting time.

Applications to CEDAC and applications to CERC will be reviewed by the
CEDAC Nominating Committee and the CERC Nominating Committee
respectively. The CEDAC and CERC application process, selection
criteria, applicant requirements, Terms of Reference, and Conflict of
Interest Guidelines are available on the CADTH web site, or by contacting CADTH at (613) 226-2553. Please
contact CADTH at or for further information. Applications
should be received by July 10, 2006.

The Canadian Agency for Drugs and Technologies in Health (CADTH) is a
significant contributor to Canada's health care systems. Federal,
provincial, and territorial health care decision makers rely on CADTH
to provide them with credible, impartial advice and evidence-based
information about the effectiveness and efficiency of drugs and other
health technologies through three programs: Health Technology
Assessment; Common Drug Review; and the Canadian Optimal Medication
Prescribing and Utilization Service.